Studies have shown that in models of osteoporosis caused by hormone deficiency, isopsoralen acts as an AhR antagonist, increases the expression of ERα, enhances bone strength and trabecular bone structure, and promotes osteoblast differentiation through the AhR/ERα pathway (Ge L. et al., 2018). Here, ESR1 is linked to osteoporosis.